Bone formation after sinus augmentation with engineered bone.

Maxillary sinus augmentation is a widely used procedure to enhance bone volume for dental implants. Autologous bone grafts have long been the gold standard due to their osteoconductive and osteoinductive properties. However, the use of autografts is limited by donor site morbidity and limited availability. Tissue-engineered bone grafts offer a potential alternative, but their clinical performance remains uncertain. Prior research has shown that autologous bone grafts provide predictable outcomes, but the resorption rates and mineralization of engineered alternatives are not well established. This gap motivated the need to compare the resorption and mineralization profiles of autologous and tissue-engineered bone grafts. No prior work had resolved the long-term stability of engineered bone in sinus augmentation. The clinical relevance of this comparison is significant for patients and surgeons seeking alternatives to autografts. Understanding the limitations of engineered grafts could guide future improvements in scaffold design and cell sourcing. This study aimed to address these uncertainties through direct clinical comparison.

The study aimed to evaluate the resorption and mineralization of tissue-engineered bone grafts in maxillary sinus augmentation. The specific problem addressed was the lack of evidence on the long-term stability of engineered bone compared to autologous grafts. The motivation was to determine whether cultured osteoblasts on synthetic scaffolds could serve as a viable alternative. The researchers focused on volume changes and bone density as key indicators of graft performance. They compared two groups: one using autologous bone and the other using engineered bone. The primary objective was to quantify the resorption rates and mineralization levels at three months post-surgery. This timeframe was selected to assess early graft integration and degradation. The study aimed to inform clinical decision-making by providing empirical data on graft reliability.

The study involved 31 patients undergoing maxillary sinus augmentation. Group 1 received autologous cancellous bone grafts from the iliac crest (n=17). Group 2 received tissue-engineered bone grafts composed of cultured human osteoblasts on PLGA scaffolds (n=14). Volume measurements were obtained using computed tomography (CT) scans pre- and post-operatively. Bone density was assessed using Hounsfield units (HU) from the same CT images. The resorption rate was calculated as the percentage change in graft volume over three months. The study design was prospective and observational, with no randomization. Patients were monitored at regular intervals to track graft behavior. The primary outcome measures were resorption rate and mineralization levels in each group.

The resorption rate for autologous bone grafts was 29% at three months post-surgery. In contrast, the tissue-engineered bone showed a significantly higher resorption rate of 90%. The autologous bone demonstrated a bone density range of 266-551 Hounsfield units (HU). Only one case of the tissue-engineered bone achieved sufficient mineralization, with a density of 152 HU. The high resorption rate of engineered bone suggests poor stability in the sinus environment. The low mineralization levels indicate limited osteogenic potential of the cultured osteoblasts. These findings highlight the limitations of the current tissue-engineered graft design. The results suggest that autologous bone remains more reliable for sinus augmentation.

The study found that autologous cancellous bone grafts provided more reliable outcomes than tissue-engineered bone in maxillary sinus augmentation. The authors suggest that the high resorption rate and low mineralization of engineered bone limit its clinical utility. They propose that further research is needed to improve the design and performance of tissue-engineered grafts. The researchers emphasize the importance of comparing engineered grafts with autografts to establish their viability. The findings do not support the widespread use of current tissue-engineered bone for sinus augmentation. The authors acknowledge the need for larger studies to confirm these results. They recommend that future investigations focus on optimizing scaffold materials and cell sources. The study concludes that autologous bone remains the preferred option for this procedure.